International review of blood donation screening for anti‐HBc and occult hepatitis B virus infection
Fu MX., Faddy HM., Candotti D., Groves J., Saa P., Styles C., Adesina O., Carrillo JP., Seltsam A., Weber‐Schehl M., O'Brien SF., Drews SJ., Aidoo NB., Pajares ÁL., Perez LN., Deng X., van de Laar T., Laperche S., Lehtisalo R., Yilmaz S., Tsoi W., Juhl D., Niederhauser C., Chenarsabz N., O'Flaherty N., Goto N., Satake M., Renaud C., Lewin A., Cloutier M., Sawadogo S., Reynolds C., Zhiburt E., Muylaert A., Van Gaever V., Garcia‐Otalora M., Jarvis L., Vermeulen M., Busch M., Blackmore S., Jones A., Brailsford S., Irving WL., Andersson M., Simmonds P., Harvala H.
AbstractBackgroundHepatitis B core antibody (anti‐HBc) screening has been implemented in many blood establishments to help prevent transmission of hepatitis B virus (HBV), including from donors with occult HBV infection (OBI). We review HBV screening algorithms across blood establishments globally and their potential effectiveness in reducing transmission risk.Materials and MethodsA questionnaire on HBV screening and follow‐up strategies was distributed to members of the International Society of Blood Transfusion working party on transfusion‐transmitted infectious diseases. Screening data from 2022 were assimilated and analyzed.ResultsA total of 30 unique responses were received from 25 countries. Sixteen respondents screened all donations for anti‐HBc, with 14 also screening all donations for HBV DNA. Anti‐HBc prevalence was 0.42% in all blood donors and 1.19% in new donors in low‐endemic countries; however, only 44% of respondents performed additional anti‐HBc testing to exclude false reactivity. 0.68% of anti‐HBc positive, HBsAg‐negative donors had detectable HBV DNA. Ten respondents did universal HBV DNA screening without anti‐HBc, whereas four respondents did not screen for either. Deferral strategies for anti‐HBc positive donors were highly variable. One transfusion‐transmission from an anti‐HBc negative donor was reported.DiscussionAnti‐HBc screening identifies donors with OBI but also results in the unnecessary deferral of a significant number of donors with resolved HBV infection and donors with false‐reactive anti‐HBc results. Whilst confirmation of anti‐HBc results could be improved to reduce donor deferral, transmission risks associated with anti‐HBc negative OBI donors must be considered. In high‐endemic areas, highly sensitive HBV DNA testing is required to identify infectious donors.